2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Conditions
Fasting
9
Prostatic Neoplasms
3
Breast Neoplasms
3
Intermittent Fasting
2
Colorectal Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Solitary Fibrous Tumors
1
Sarcoma
1
Polycystic Ovary Syndrome
1
Ovarian Neoplasms
1
Neoplasms
1
Lymphoma
1
Liposarcoma
1
Infertility
1
Histiocytoma, Malignant Fibrous
1
Glioma
1
Fibrosis
1
Fasting in Malignant Solid Tumors
1
Esophageal Neoplasms
1
Dermatofibrosarcoma
1
Childhood Cancer Survivors
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Doxorubicin
9
Imatinib Mesylate
6
pazopanib
4
Ifosfamide
4
Radiotherapy
3
Gemcitabine
3
Docetaxel
3
pembrolizumab
2
Radiation
2
Neoadjuvant Therapy
2
Mohs Surgery
2
Biopsy
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
selinexor
1
saracatinib
1
sapanisertib
1
ribociclib
1
peposertib
1
liposomal doxorubicin
1
indolepropanol phosphate
1
envafolimab
1
cixutumumab
1
brigimadlin
1
avelumab
1
X-Rays
1
Watchful Waiting
1
TTI-621
1
Sunitinib
1
Specimen Handling
1
Razoxane
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Dermatofibrosarcoma
×
Angptl4 protein, mouse
×
Clear all
NCT06789172
2026-05-22
INVOKE
Epkin
Phase 1
Recruiting
166 enrolled